HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
Breast Cancer Update
00:00
How are ADCs being evaluated in localized and post‑neoadjuvant settings?
Dr Huppert outlines neoadjuvant and post‑neoadjuvant ADC trials including I‑SPY, phase III Dato‑DXd vs Keynote‑522, and ASCENT‑O5.
Play episode from 35:44
Transcript
